324 related articles for article (PubMed ID: 9193366)
21. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Bastion Y; Coiffier B; Brice P; Bosly A; Dupriez B; Nouvel C; Tilly H; Lederlin P; Biron P; Brière J; Gaulard P; Reyes F
J Clin Oncol; 1997 Mar; 15(3):1131-7. PubMed ID: 9060555
[TBL] [Abstract][Full Text] [Related]
22. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
23. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
24. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
[TBL] [Abstract][Full Text] [Related]
25. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Bartlett NL; Kwak LW; Horning SJ
Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238
[TBL] [Abstract][Full Text] [Related]
26. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma.
Binn M; Ruskoné-Fourmestraux A; Lepage E; Haioun C; Delmer A; Aegerter P; Lavergne A; Guettier C; Delchier JC
Ann Oncol; 2003 Dec; 14(12):1751-7. PubMed ID: 14630680
[TBL] [Abstract][Full Text] [Related]
27. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
Vitolo U; Bertini M; Brusamolino E; Cavallero GB; Comotti B; Gallo E; Ghio R; Levis A; Luxi G; Meneghini V
J Clin Oncol; 1992 Feb; 10(2):219-27. PubMed ID: 1370690
[TBL] [Abstract][Full Text] [Related]
28. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
29. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
Brice P; Bastion Y; Lepage E; Brousse N; Haïoun C; Moreau P; Straetmans N; Tilly H; Tabah I; Solal-Céligny P
J Clin Oncol; 1997 Mar; 15(3):1110-7. PubMed ID: 9060552
[TBL] [Abstract][Full Text] [Related]
30. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Rodriguez J; McLaughlin P; Hagemeister FB; Fayad L; Rodriguez MA; Santiago M; Hess M; Romaguera J; Cabanillas F
Blood; 1999 Apr; 93(7):2202-7. PubMed ID: 10090928
[TBL] [Abstract][Full Text] [Related]
31. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
32. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
33. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Adida C; Haioun C; Gaulard P; Lepage E; Morel P; Briere J; Dombret H; Reyes F; Diebold J; Gisselbrecht C; Salles G; Altieri DC; Molina TJ
Blood; 2000 Sep; 96(5):1921-5. PubMed ID: 10961895
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B
Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634
[TBL] [Abstract][Full Text] [Related]
36. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Bosly A; Tilly H; Morel P; Nouvel C; Herbrecht R; D'Agay MF
J Clin Oncol; 1994 Dec; 12(12):2543-51. PubMed ID: 7527453
[TBL] [Abstract][Full Text] [Related]
37. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
[TBL] [Abstract][Full Text] [Related]
38. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
39. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
[TBL] [Abstract][Full Text] [Related]
40. [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
Yang H; Lang RG; Liu FF; Wang XF; Jin ZJ; Lü AJ; Wang Y; Fu XL; Fu L
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):79-84. PubMed ID: 21426801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]